Extent of resection and radiotherapy in GBM: A 1973 to 2007 surveillance, epidemiology and end results analysis of 21,783 patients

Zinn,Pascal O.; Colen,Rivka R.; Kasper,Ekkehard M.; Burkhardt,Jan-Karl

doi:10.3892/ijo.2013.1770

Extent of resection and radiotherapy in GBM: A 1973 to 2007 surveillance, epidemiology and end results analysis of 21,783 patients

Authors:
- Pascal O. Zinn
- Rivka R. Colen
- Ekkehard M. Kasper
- Jan-Karl Burkhardt
View Affiliations

Affiliations: Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA, Department of Radiology, M.D. Anderson Cancer Center, University of Texas, Houston, TX, USA, Department of Surgery, Division of Neurosurgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA, Department of Neurosurgery, University Hospital, Zurich, Switzerland
Published online on: January 15, 2013 https://doi.org/10.3892/ijo.2013.1770
Pages: 929-934

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Surgery, radiation and chemotherapy are the standard of care for GBM patients, however, the impact of extent of resection (EOR) and radiotherapy (RT) on patient survival across age groups has not been established. Therefore, we present the current largest study on EOR and RT in GBM over the past three decades. Using the population based Surveillance, Epidemiology and End Results (SEER) registry, we identified a total of 21,783 GBM patients (1973‑2007). Survival analysis based on EOR and RT was performed by means of factor analysis, Kaplan‑Meier survival and Cox proportional hazard's ratio. Age, RT and EOR were highly prognostic (p<0.00001). Combined gross total resection (GTR) and RT showed the longest median survival (11 months) compared to subtotal resection (STR) and RT (9 months). Survival times after monotherapy with RT, GTR and STR were 5, 3 and 2 months, respectively. Patients without therapy showed a median survival of 1 month. RT and GTR demonstrated highest median survival. Interestingly, survival advantage of GTR versus STR amounted to only 1-2 months. Monotherapy (GTR, STR or RT) showed a significantly lower survival rate compared to combination therapies. RT alone yielded significantly better survival compared to any resective approach. Relative to overall age-specific median survival, elderly patients still reasonably benefit from RT alone. However, across all age groups multimodality treatment with surgery and RT continues to provide the largest survival benefit compared to either treatment alone and, thus, should be pursued whenever feasible.

View Figures

View References

1	Hess KR, Broglio KR and Bondy ML: Adult glioma incidence trends in the United States, 1977–2000. Cancer. 101:2293–2299. 2004.PubMed/NCBI
2	Buckner JC: Factors influencing survival in high-grade gliomas. Semin Oncol. 30:10–14. 2003. View Article : Google Scholar
3	Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
4	Iwamoto FM, Reiner AS, Nayak L, Panageas KS, Elkin EB and Abrey LE: Prognosis and patterns of care in elderly patients with glioma. Cancer. 115:5534–5540. 2009. View Article : Google Scholar : PubMed/NCBI
5	Lacroix M, Abi-Said D, Fourney DR, et al: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 95:190–198. 2001. View Article : Google Scholar : PubMed/NCBI
6	Lamborn KR, Chang SM and Prados MD: Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol. 6:227–235. 2004. View Article : Google Scholar : PubMed/NCBI
7	Lefranc F, Rynkowski M, DeWitte O and Kiss R: Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. Adv Tech Stand Neurosurg. 34:3–35. 2009.PubMed/NCBI
8	Li SW, Qiu XG, Chen BS, et al: Prognostic factors influencing clinical outcomes of glioblastoma multiforme. Chin Med J (Engl). 122:1245–1249. 2009.PubMed/NCBI
9	McGirt MJ, Chaichana KL, Gathinji M, et al: Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 110:156–162. 2009. View Article : Google Scholar : PubMed/NCBI
10	Sanai N and Berger MS: Glioma extent of resection and its impact on patient outcome. Neurosurgery. 62:753–764. 2008. View Article : Google Scholar : PubMed/NCBI
11	Sanai N, Polley MY, McDermott MW, Parsa AT and Berger MS: An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 115:3–8. 2011. View Article : Google Scholar : PubMed/NCBI
12	Scott J, Tsai YY, Chinnaiyan P and Yu HH: Effectiveness of radiotherapy for elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys. 81:206–210. 2011. View Article : Google Scholar : PubMed/NCBI
13	Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009.
14	Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
15	CBTRUS: Central Brain Tumor registry of the United States. http://www.cbtrus.org/. 2008.
16	Zinn PO, Sathyan P, Mahajan B, Bruyere J, Hegi M, Majumder S and Colen RR: A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature. PLoS One. 7:e415222012.PubMed/NCBI
17	Marko NF, Toms SA, Barnett GH and Weil R: Genomic expression patterns distinguish long-term from short-term glioblastoma survivors: a preliminary feasibility study. Genomics. 91:395–406. 2008. View Article : Google Scholar
18	Phillips HS, Kharbanda S, Chen R, et al: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 9:157–173. 2006. View Article : Google Scholar
19	Colman H, Zhang L, Sulman EP, et al: A multigene predictor of outcome in glioblastoma. Neuro Oncol. 12:49–57. 2010. View Article : Google Scholar : PubMed/NCBI
20	Cooper LA, Gutman DA, Long Q, et al: The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One. 5:e125482010. View Article : Google Scholar : PubMed/NCBI
21	Zinn PO, Majadan B, Sathyan P, et al: Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS One. 6:e254512011. View Article : Google Scholar : PubMed/NCBI
22	Johnson DR and O’Neill BP: Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 107:359–364. 2012. View Article : Google Scholar : PubMed/NCBI
23	Koshy M, Villano JL, Dolecek TA, et al: Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 107:207–212. 2012. View Article : Google Scholar : PubMed/NCBI
24	Barnholtz-Sloan JS, Sloan AE and Schwartz AG: Racial differences in survival after diagnosis with primary malignant brain tumor. Cancer. 98:603–609. 2003. View Article : Google Scholar : PubMed/NCBI
25	Barnholtz-Sloan JS, Maldonado JL, Williams VL, et al: Racial/ethnic differences in survival among elderly patients with a primary glioblastoma. J Neurooncol. 85:171–180. 2007. View Article : Google Scholar : PubMed/NCBI
26	Ang C, Guiot MC, Ramanakumar AV, Roberge D and Kavan P: Clinical significance of molecular biomarkers in glioblastoma. Can J Neurol Sci. 37:625–630. 2010. View Article : Google Scholar : PubMed/NCBI
27	Kanu OO, Hughes B, Di C, et al: Glioblastoma multiforme oncogenomics and signaling pathways. Clin Med Oncol. 3:39–52. 2009.PubMed/NCBI
28	Chang JE, Khuntia D, Robins HI and Mehta MP: Radiotherapy and radiosensitizers in the treatment of glioblastoma multi-forme. Clin Adv Hematol Oncol. 5:894–915. 2007.PubMed/NCBI
29	Clarke J, Butowski N and Chang S: Recent advances in therapy for glioblastoma. Arch Neurol. 67:279–283. 2010. View Article : Google Scholar
30	Keime-Guibert F, Chinot O, Taillandier L, et al: Radiotherapy for glioblastoma in the elderly. N Engl J Med. 356:1527–1535. 2007. View Article : Google Scholar : PubMed/NCBI
31	Lai R, Hershman DL, Doan T and Neugut AI: The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme. Neuro Oncol. 12:190–198. 2010. View Article : Google Scholar : PubMed/NCBI